Premium
p53 expression and prognosis in gastric carcinoma
Author(s) -
Martin Hilary M.,
Filipe M. Isabel,
Morris Richard W.,
Lane David P.,
Silvestre Frederico
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910500604
Subject(s) - immunoperoxidase , oncogene , carcinoma , cancer , hepatocellular carcinoma , odds ratio , medicine , immunohistochemistry , pathology , survival analysis , tumor suppressor gene , biology , oncology , cancer research , antibody , monoclonal antibody , carcinogenesis , immunology , cell cycle
Abnormalities of the p53 gene have been identified in many malignancies, with reports of aberration in over half of colorectal, lung, breast and hepatocellular carcinoma cases. The normal gene acts as a recessive oncogene, while mutations change the apparent function to that of a dominant oncogene. In this investigation a 3‐layered immunoperoxidase technique was applied to routinely fixed and paraffin‐embedded tissue sections from 125 gastric carcinomas, using a polyclonal anti‐p53 antibody (CM‐1). We found that 57% of these carcinomas expressed high levels of p53 protein (positive nuclear staining). Survival analysis revealed a strong association between p53 status of the tumour and patient survival time after diagnosis (p = 0.02, Mantel‐Cox Test); odds ratio of death, 2.09 (95% confidence interval 1.02 to 4.25). The 5‐year survival of patients with p53‐expressing tumours was 24%, compared with 56% for those non‐p53‐expressing tumours (the median survival times were 13 and 102 months, respectively).